Clinical trials: Osteoporosis Postmenopausal
OSTEOPOROSIS, POSTMENOPAUSAL
Risedronate in Postmenopausal Women With Low Bone Density
The primary objective of this pilot study is to estimate the percent change from baseline at Week 4, Month 6 in NTX bone turnover marker for a monthly 150mg dose of risedronate administered for 6 months and a loading dose regimen…
- Trial name
- NCT00351091
- Testing
- RISEDRONATE
- Volunteers
- 150 people
- Sponsor
- Sanofi
Postmenopausal Osteoporosis
Anabolic Therapy in Postmenopausal Osteoporosis
In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.
- Trial name
- NCT05010590
- Testing
- Romosozumab, Denosumab
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Osteoporosis, Postmenopausal
Intervention on Osteoporosis and Chronic Kidney Disease-mineral and Bone Disorder (CKD-MBD)
Older adults having chronic kidney disease (CKD) have a higher rate of fracture than those without chronic kidney disease. Osteoporosis and chronic kidney disease mineral and bone disorder (CKD-MBD) are risk factors for skeletal…
- Trial name
- NCT04271605
- Testing
- diet and exercise suggestion
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- National Taiwan University Hospital
Osteoporosis
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
The aim of this study was to examine the effect of zoledronic acid and alendronate on bone metabolism as measured by biomarkers in postmenopausal women with osteoporosis.
- Trial name
- ROSE (NCT00404820)
- Testing
- Zoledronic acid 5 mg solution, Alendronate 70 mg tablets, Calcium/Vitamin D
- Where
- Germany
- Volunteers
- 604 people
- Sponsor
- Novartis
Osteoporosis
Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)
The primary objective of this trial is to show that PTH(1-84) is superior to strontium ranelate in bone formation measured as changes in bone formation markers over a treatment period of 24 weeks in postmenopausal women with…
- Trial name
- NCT00479037
- Testing
- Full Length Parathyroid Hormone, PTH(1-84), Strontium Ranelate
- Where
- Denmark
- Volunteers
- 82 people
- Sponsor
- Nycomed
Osteoporosis, Postmenopausal
A Clinical Trial to Evaluate the Safety and Pharmacokinetic
A phase 1 clinical trail to evaluate the safety and pharmacokinetic characteristic after administration of fixed-dose combination or loose combination of HUG186 in healthy adult male or menopausal female volunteers
- Trial name
- NCT03475719
- Testing
- HUG186-B and HUG186-D, HUG186
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Osteoporosis
A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture
This study will evaluate whether teriparatide is superior to the active comparator in the change from baseline of lumbar spine BMD (bone mineral density) in men and postmenopausal women with low bone mass and a recent…
- Trial name
- MOVE (NCT00887354)
- Testing
- Teriparatide, Risedronate, Calcium
- Where
- 28 sites in United States, Canada and 10 more
- Volunteers
- 224 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment
The purpose of this study is to evaluate the use of an oral bisphosphonate (alendronate) in preventing bone loss in postmenopausal women with early breast cancer who are receiving anastrozole therapy, and to determine how long…
- Trial name
- BATMAN (NCT00122356)
- Testing
- Alendronate sodium
- Where
- 8 sites in Australia
- Volunteers
- 303 people
- Sponsor
- Barwon Health
Postmenopausal Osteoporosis
PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia
The purpose of this study is to evaluate treatment adherence to different regimens of ibandronate in postmenopausal women with osteoporosis or osteopenia who are intolerant to daily or weekly alendronate or risedronate therapy…
- Trial name
- NCT02598453
- Testing
- Ibandronate
- Where
- 60 sites in United States
- Volunteers
- 545 people
- Sponsor
- Hoffmann-La Roche
Low Bone Mineral Density, Postmenopausal Osteoporosis
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
The primary objective was to determine the effect of treatment with romosozumab versus placebo at month 12 on the percent change from baseline in bone mineral density (BMD) at the lumbar spine in postmenopausal women with low…
- Trial name
- NCT00896532
- Testing
- Alendronate, Teriparatide, Romosozumab
- Volunteers
- 419 people
- Sponsor
- Amgen
Osteoporosis, Postmenopausal
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis
The purpose of this study is to demonstrate similar efficacy and safety between TVB-009 and Prolia® (denosumab)
- Trial name
- NCT04729621
- Testing
- TVB-009, Prolia®
- Where
- 78 sites in United States, Bulgaria and 8 more
- Volunteers
- 332 people
- Sponsor
- Teva Pharmaceuticals USA
Postmenopausal Osteoporosis
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
The purpose of this trial is to study the efficacy of a 35 mg delayed release weekly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.
- Trial name
- NCT00541658
- Testing
- risedronate
- Where
- 45 sites in United States, Argentina and 6 more
- Volunteers
- 923 people
- Sponsor
- Warner Chilcott
Postmenopausal Osteoporosis
Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers
CMAB807 is a human monoclonal antibody targeting the key bone resorption mediator RANKL. The drug is administered via subcutaneous injection once six months and is approved for various indications, including the treatment of…
- Trial name
- NCT03925051
- Testing
- Prolia®, CMAB807
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Shanghai Biomabs Pharmaceutical Co., Ltd.
Low Bone Density, Osteoporosis
Effects of DHEA and Exercise on Bone Marrow Fat in Postmenopausal Women
Bone strength -the main determinant of bone fracture- is a function not only of bone mineral density (BMD) and microstructure, but also of its microenvironment, including bone marrow fat (BMF).
- Trial name
- NCT05316272
- Testing
- Exercise, DHEA
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Colorado, Denver
Osteoporosis
Nitrates and Bone Turnover; Nitrates and Bone Turnover Bisphosphonate Sub-Study
Purpose: NABT: To compare five widely available nitrate formulations: (1) 15 of nitroglycerin (NTG) ointment, (2) 0.3 mg and (3) 0.6 mg of sublingual NTG, (4) 20 mg of isosorbide mononitrate (an oral tablet), and (5) 160 mg of…
- Trial name
- NABT;NABT-B (NCT01387672)
- Testing
- Nitrates (NABT Main trial)
- Where
- Canada
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Postmenopausal Women With Osteoporosis
Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis
A multicenter, randomized, double-blind, active-controlled, phase III clinical trial to evaluate the efficacy and safety of Dp-R206 and Bonviva for 16 weeks once a month on the improvement of vitamin D in postmenopausal women…
- Trial name
- DIOS (NCT01581320)
- Testing
- Test group, Reference group
- Where
- South Korea
- Volunteers
- 201 people
- Sponsor
- Alvogen Korea
Osteoporosis
Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density
This study will evaluate the effect of a 1-year administration of the vitamin D analog 2-methylene-19-nor-(20S)-1alpha, 25-dihydroxyvitamin D3 (DP001) on bone mineral density (BMD), safety, and tolerability.
- Trial name
- 2MD-3H-2B (NCT00715676)
- Testing
- DP001
- Where
- 9 sites in United States
- Volunteers
- 157 people
- Sponsor
- Deltanoid Pharmaceuticals
Osteoporosis, Bone Loss, Age Related
Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women
To develop a decision aid to support the decision to use (or not use) bisphosphonates in postmenopausal women at risk for osteoporotic fractures, and to assess the impact of the decision aid on start and six month adherence to…
- Conditions
- Osteoporosis, Bone Loss, Age Related, Postmenopausal Bone Loss, Postmenopausal Osteoporosis
- Trial name
- NCT00578981
- Testing
- Osteoporosis Choice Decision Aid
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Vitamin D Deficiency, Osteoporosis
Change in Free 25(OH)D After High Dose in Vitamin D Deficient Postmenopausal Women
Total 25(OH)D is currently used as a biomarker of vitamin D status. However, there is some debate as to whether total 25(OH)D is the best marker to use.
- Trial name
- NCT02553044
- Testing
- Cholecalciferol (Vitamin D3)
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Post Menopausal Osteoporosis
A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
This 2 arm crossover study will evaluate patient reported preference for either once monthly Boniva (150mg p.o.) or once weekly risedronate (35mg p.o.).
- Trial name
- NCT00377234
- Testing
- Risedronate, ibandronate [Bonviva/Boniva]
- Where
- 48 sites in United States
- Volunteers
- 356 people
- Sponsor
- Hoffmann-La Roche